Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types
Jammbe Z. Musoro, Corneel Coens, Mirjam A. G. Sprangers et al. · European Journal of Cancer · 2023
INTRODUCTION: Early guidelines for minimally important differences (MIDs) for the EORTC QLQ-C30 proposed ≥10 points change as clinically meaningful for all scales. Increasing evidence that MIDs can vary by scale, direction of change, cancer type and estimation method has raised doubt about a single global standard. This paper identifies MID patterns for interpreting group-level change in EORTC QLQ-C30 scores across nine cancer types. METHODS: Data were obtained from 21 published EORTC Phase III trials that enroled 13,015 patients across nine cancer types (brain, colorectal, advanced breast, head/neck, lung, mesothelioma, melanoma, ovarian, and prostate). Anchor-based MIDs for within-group change and between-group differences in change over time were obtained via mean change method and linear regression, respectively. Separate MIDs were estimated for improvements and deteriorations. Distribution-based estimates were derived and compared with anchor-based MIDs. RESULTS: Anchor-based MIDs mostly ranged from 5 to 10 points. Differences in MIDs for improvement vs deterioration, for both within-group and between-group, were mostly within a 2-points range. Larger differences between within-group and between-group MIDs were observed for several scales in ovarian, lung and head/neck cancer. Most anchor-based MIDs ranged between 0.3 SD and 0.5 SD distribution-based estimates. CONCLUSIONS: Our results reinforce recent claims that no single MID can be applied to all EORTC QLQ-C30 scales and disease settings. MIDs varied by scale, improvement/deterioration, within/between comparisons and by cancer type. Researchers applying commonly used rules of thumb must be aware of the risk of dismissing changes that are clinically meaningful or underpowering analyses when smaller MIDs apply.
Cited by 192 works. doi:10.1016/j.ejca.2023.04.027 Open-access PDF
Authors
- Jammbe Z. Musoro
- Corneel Coens
- Mirjam A. G. Sprangers
- Yvonne Brandberg
- Mogens Grøenvold
- Hans‐Henning Flechtner
- Kim Cocks
- Galina Velikova
- Linda Dirven
- Elfriede Greimel
- Susanne Singer
- Katarzyna Pogoda
- Eva‐Maria Gamper
- Samantha Claire Sodergren
- Alexander M.M. Eggermont
- Michael T Koller
- Jaap C. Reijneveld
- MARTIN J.B. TAPHOORN
- Madeleine Trudy King
- Andrew Bottomley
References
- Prospect Theory: An Analysis of Decision under Risk
- Interpreting the significance of changes in health-related quality-of-life scores.
- Methods to Explain the Clinical Significance of Health Status Measures
- Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes
- Reporting of Patient-Reported Outcomes in Randomized Trials
- Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire.
- A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale
- A point of minimal important difference (MID): a critique of terminology and methods
- Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
- Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols